after VTP with only 2 mice presenting levels >0.1. After 4 weeks, one mouse still had undetected PSA (<0.1) CONCLUSIONS: In a preclinical prostate cancer model using VTP ablation, we show that RSOM and 68 Ga-PSMA PET-CT are promising imaging approaches. We demonstrate that RSOMmeasured vessels density can predict the success of ablation before VTP and 68 Ga-PSMA PET-CT signal can predict relapse after VTP ablation, that outperform blood PSA level.
INTRODUCTION AND OBJECTIVES: Apparent diffusion coefficient (ADC) is expected to reflect tumor aggressiveness. In prostate cancer (PC), however, the use of ADC value (ADCV) is limited to the peripheral zone (PZ) because of the background signal, especially in the transition zone (TZ). We assessed the usefulness of ADC ratio (ADCR) in predicting ISUP grade groups on radical prostatectomy (RP-GG) and subsequent biochemical recurrence (BCR) by prostatic zone.
METHODS: We enrolled 284 clinically localized PC patients who had undergone multiparametric MRI, systematic biopsy, and RP. A region of interest (ROI) was drawn outlining the index tumor on ADC map. Another equal-sized ROI was drawn symmetrically in the contralateral lobe and adjusted to include normal regions if necessary. ADCR was calculated by dividing the tumor ADCV by the contralateral ADCV. ADC metrics were examined for associations with RP-GG and BCR using Spearman's coefficient and logistic or Cox regression, and their predictive ability was assessed using the area under the curve (AUC) or concordance (c-) index. Cutoffs of variables were set to obtain their best performance.
RESULTS The use of MRI assistance in the diagnosis and surveillance of men with prostate cancer has become increasingly more widespread. The aim of our study was to determine the rate of pathology upgrading in men when MRI-guided fusion biopsy (FBx) is used after regular systematic/template biopsy (TRUS Bx), and to determine factors predictive of upgrading.
METHODS: We conducted a retrospective review of all patients who underwent FBx (targeted MRI lesion plus 12-core template biopsy) at our institution between 2015 and 2018. Only patients with previous diagnosis of atypical small acinar proliferation (ASAP) or on active surveillance for prostate cancer diagnosed and previously surveyed by TRUS Bx were included. Any patients with >3 years between regular and FBx were excluded. Patient demographic data included age, number of regular biopsies before FBx, PIRADS grading of MRI lesion, PSA immediately prior to FBx, and time interval between regular and MRI biopsy. Outcome was rate of upgrading between TRUS Bx and FBx. Upgrading was defined as increase in Gleason grade and/or new positive core in a different prostate region on FBx. Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1163
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